Anixa Biosciences Inc., a biotechnology company dedicated to cancer treatment and prevention, has announced a forthcoming presentation on its Phase 1 clinical trial for an ovarian cancer CAR-T immunotherapy. Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and the trial's principal investigator, will present the e-poster at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025. The event is scheduled to take place from June 19-21, 2025, in Vienna, Austria. The trial involves autologous T-cells genetically engineered with a chimeric receptor aimed at targeting the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation will provide insights into the preliminary findings of this ongoing study.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。